Drugs / Benapenem
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04476407 | Jun → Oct 2019 | urinary tract infection | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03570970 | Mar → Jun 2016 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03588156 | Mar → Sep 2015 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04505683 | Dec 2018 → May 2020 | acute pyelonephritis | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benapenem | “Multiple-dose Tolerability and Pharmacokinetic Studies of Benapenem inClinical Healthy Subjects” NCT03570970 ↗ |
| Modality | Small molecule | — CHEMBL5095168 ↗ |
| Route | Intravenous | “Each subject only receives one dose, intravenous drip, once daily, for 7 consecutive days” NCT03570970 ↗ |